Experience with fingolimod in clinical practice

International Journal of Neuroscience

Volumn 125, Issue 9, 2015, Pages 678-685

  Hersh, Carrie M ^a   Hara Cleaver, Claire ^a   Rudick, Richard A ^b   Cohen, Jeffrey A ^a   Bermel, Robert A ^a   Ontaneda, Daniel ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b BIOGEN   (United States)

Author keywords

clinical practice; disease activity; fingolimod; multiple sclerosis; tolerability

Indexed keywords

FINGOLIMOD; GADOLINIUM; NATALIZUMAB; IMMUNOSUPPRESSIVE AGENT;

ADULT; ALLERGIC REACTION; ALOPECIA; ARTICLE; CLINICAL PRACTICE; CONTRAST ENHANCEMENT; DIZZINESS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTRONIC MEDICAL RECORD; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HEART DISEASE; HUMAN; HYPERTRANSAMINASEMIA; INFECTION; LEUKOPENIA; LUNG DISEASE; MACULAR EDEMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT PREFERENCE; PRESCRIPTION; QUALITY OF LIFE; RELAPSE; UNIVERSITY HOSPITAL; MIDDLE AGED; OUTCOME ASSESSMENT;

ADULT; FEMALE; FINGOLIMOD HYDROCHLORIDE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 84939235786     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2014.969839     Document Type: Article

References (18)

1. Cohen JA, Chun J. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Annals Neurol 2011; 69: 759-77.
2. Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 2010; 33: 91-101.
3. Brinkmann V, Davis MD, Heise CE., et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002; 277: 21453-7.
4. Kappos L, Radue E-W, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401.
5. Calabresi PA, Goodin DS, Jeffery D, et al. Efficacy and safety of fingolimod versus placebo: primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing-remitting multiple sclerosis. 2012.
6. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-15.
7. Highlights of Prescribing Information for Gilenya (fingolimod) capsules. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/022527s008lbl.pdf. Accessed May 2012.
8. Clifford DB, DeLuca A, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010; 9: 438-46.
9. Ermis U, Weis J, Schulz J. PML in a patient treated with fumaric acid. N Engl J Med 2013; 368 (17): 1657-8.
10. Ontaneda D, Hara-Cleaver C, Rudick RA, et al. Early tolerability and safety of fingolimod in clinical practice. J Neurol Sci 2012; 323: 167-72.
11. Rudick RA, Cutter G, Reingold S. The Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis trials. Mult Scler 2002; 8: 359-65.
12. Schwartz CE, Vollmer T, Lee H. Reliability and validity of two self-report measures of impairment and disability for MS. North American Research Consortium on Multiple Sclerosis Outcomes Study Group. Neurology. 1999; 52: 63-70.
13. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Int Med 2001; 16: 606-13.
14. EuroQol-a new facility for the measurement of health-related quality of life. The EuroQol Group 1990; 16: 199-208.
15. de Seze J, Ongagna J, Zaenker C, et al. Reduction of washout delay between Tysabri and Gilenya: a regional real-life story. 2013.
16. Kappos L, Radue EW, Comi G, et al. Disease control and safety in relapsing-remitting multiple sclerosis (RRMS) patients switching from natalizumab to fingolimod: a 32-week, rater-and patient-blind, randomized, parallel-group study (TOFINGO). Presented at ECTRIMS, 2-5 October 2013, Copenhagen, Denmark.
17. Cohen M, Maillart E, Tourbah A, et al. Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study. J Am Med Assoc 2014; 71: 436-441.
18. Collins W, Cohen J, O'Connor P, et al. Long-term safety of oral fingolimod (FTY720) in relapsing multiple sclerosis: integrated analyses of phase 2 and 3 studies (P843). Mult Scler 2010; 16 (Suppl 10): S295.